Abstract: L-arginine found essential to enhance the glomerular function of the kidneys is used &phgr; formulate a low viscosity, calorie-dense, nutritional product for a person having renal failure. In a product free of citric acid or citrates, for oral ingestion, the taste of arginine is counteracted by lactic, malic or adipic acid; in a formulation for tube-feeding, citric acid and citrates in a specified ratio controls the product's stability. The ratio of calcium to phosphorus is controlled, as is the caloric distribution and water content; the amounts of vitamins and minerals included provide a nutritionally complete formulation.

Abstract: A child-resistant, adult friendly package is disclosed. The package is designed to require a sequence of opening steps too complex for a child to perform, but simple enough for an adult to perform. The package is formed from a top having a surface that projects from one face of the top sheet and forms a recess in the opposite face of the top sheet, a bottom sheet overlying the opposite face of the top sheet, arranged to enclose the recess, a sealed portion and an unsealed portion formed between the top sheet and the bottom sheet, wherein each recess is associated with a sealed portion and an unsealed portion, and a tear slit located between the unsealed portion and an edge of the package, wherein the tear slit does not contact any edge of the package.

Abstract: Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an anti-oxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.

Abstract: Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an antioxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.

Abstract: The invention is concerned with a parenteral formulation comprising a 5H-dibenz(b,f)azepine-5-carboxamide and an aqueous-based solvent. The parenteral formulation is useful in the treatment of seizures resulting from, e.g. epileptic attack.

Abstract: This invention provides a pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to release mycophenolate in the upper part of the intestinal tract.

Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.

Abstract: L-arginine found essential to enhance the glomerular function of the kidneys is used to formulate a low viscosity, calorie-dense, nutritional product for a person having renal failure. In a product free of citric acid or citrates, for oral ingestion, the taste of arginine is counteracted by lactic, malic or adipic acid; in a formulation for tube-feeding, citric acid and citrates in a specified ratio controls the product's stability. The ratio of calcium to phosphorus is controlled, as is the caloric distribution and water content; the amounts of vitamins and minerals included provide a nutritionally complete formulation.

Abstract: Pharmaceutical compositions comprising a cyclosporin in a novel galenic formulations for oral administration. The compositions typically comprise a cyclosporin, 1,2-propylene glycol, a mixed mono-,di- and tri-glyceride and a hydrophilic surfactant. Further a refined glycerol-transesterified corn oil is provided representing a mixed mono-, di- and tri-glyceride suitable for the novel formulation. Dosage forms include in particular oral dosage forms.

Abstract: An oral dosage form comprising fluvastatin and HPMC, which oral dosage form is color-stable upon prolonged periods of storage.

Abstract: A process for preparing an emulsion composition comprising a cyclosporin, a rapamycin or an ascomycin or a derivative thereof as active agent, which process comprises the step of admixing to a placebo fat emulsion a concentrate comprising a) the active agent, b) a stabiliser selected from a phospholipid, a glycolipid, a sphingolipid, a diacylphosphatidyl glycerol, an egg-phosphatidylglycerol, a soy-phosphatidylglycerol, a diacylphosphatidylglycerol, or a salt thereof; or a saturated, mono- or di-unsaturated (C12-24) fatty acid, or a salt thereof, and c) an organic solvent, wherein the weight ratio of active agent to stabiliser is between 400:1 and 0.5:1. The invention also provides ready-to-use emulsions, e.g. for intravenous administration, prepared using the above process.

Abstract: The package is designed to require a sequence of opening steps too complex for a child to perform, but simple enough for an adult to perform. The package is formed from a top having a surface that projects from one face of the top sheet and forms a recess in the opposite face of the top sheet, a bottom sheet overlying the opposite face of the top sheet, arranged to enclose the recess, a sealed portion and an unsealed portion formed between the top sheet and the bottom sheet, wherein each recess is associated with a sealed portion and an unsealed portion, and a tear slit located between the unsealed portion and an edge of the package, wherein the tear slit does not contact any edge of the package.

Abstract: The present invention is directed to patient-controlled, flexible-dosing methods of treatment utilizing transdermal nicotine patch devices, optionally with other nicotine delivery systems, to abate the use of tobacco in humans.

Abstract: An improved thickened instant coffee beverage mix, containing a mix of from about 15-90%, preferably 27%, maltodextrin with the rest, to 100%, of an agglomerated starch, and also 0.2-0.3% of mono and diglycerides, together with coffee flavorants, which can be quickly dissolved in water of at least 120° F water without delay or forming clumps.

Abstract: Method for the acylation of amines are disclosed in which includes reacting a first reactant containing an amine group with a second reactant containing an acyl halide group, wherein the reaction takes place in the presence of secondary carboxylic acid salt form, of formula I: R4R5CHCOOH  I wherein R4 is an alkyl group having 1 to 10 carbon atoms; and R5 is an alkyl group having 1 to 10 carbon atoms.

Abstract: The invention relates to a pharmaceutical preparation, which contains an immunosuppressive active agent in dissolved form in a starch capsule, or hard or soft gelatin capsule which has been coated with one or several polymer films. The invention further relates to a process for the production of the pharmaceutical preparation.

Abstract: A pharmaceutical composition in the form of a solid dispersion comprising a macrolide, e.g. a rapamycin or an ascomycin, and a carrier medium.

Abstract: A controlled release lozenge having pleasant organoleptic properties, said lozenge consisting essentially of (a) a soluble filler which is selected from the group consisting of maltitol, xylitol, sorbitol, mannitol, lactose, dextrose, saccharose, fructose, and mixtures thereof; (b) an insoluble film forming agent which is capable of forming an insoluble matrix, said insoluble film forming agent is selected from the group consisting of a polyacrylate, ethyl cellulose, polyvinylchloride, cellulose acetate, cellulose acetate phthalate, and shellac; (c) a swellable polymer which is selected from the group consisting of xanthan gum, guar gum, alginic acid or a salt thereof, pectin, polyvinyl alcohol, polysaccharide, and cellulose derivatives; and (d) at least one active substance.

Abstract: Abrasive articles comprising a cured thermosetting binder and abrasive grains. The binder is prepared with a poly-functional molecule comprising at least two functional groups selected from the group consisting of carboxyl and anhydride, and a crosslinking agent which is selected from the group consisting of a mono(hydroxyalkyl)urea comprising a single urea group, a single hydroxyl group, and at least two carbon atoms disposed between the urea group and the hydroxyl group, and 2-oxazolidone. The abrasive articles comprise bonded, nonwoven or coated abrasive articles.

Abstract: The invention is directed to aqueous coating compositions which are freeze-thaw stable in the absence of conventional volatile coalescing solvents and volatile freeze-thaw (F/T) additives and which utilize a latex binder which contains an EVA thermoplastic interpolymer which is prepared by emulsion polymerization of ethylene, vinyl acetate and a monomer represented by structure (I) ##STR1## where R is hydrogen or a methyl group, X is O or NH, and n is an integer from 1 to 11 and to the latex binder which contains the EVA interpolymer.